Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review

Sebastien Barbarot; Natasha K. Rogers; Katrina Abuabara; Helene Aubert; Joanne Chalmers; Carsten Flohr; Jon Hanifin; Luigi Naldi; David J. Margolis; Carle Paul; Matthew J. Ridd; Marie-Louise Anna Schuttelaar; Eric Simpson; Marie Tauber; Annika Volke; Stephan Weidinger; Sally R. Wilkes; Andreas Wollenberg; Kim S. Thomas

doi:10.1016/j.jaad.2016.05.043

Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review

Sebastien Barbarot, Natasha K. Rogers, Katrina Abuabara, Helene Aubert, Joanne Chalmers, Carsten Flohr, Jon Hanifin, Luigi Naldi, David J. Margolis, Carle Paul, Matthew J. Ridd, Marie-Louise Anna Schuttelaar, Eric Simpson, Marie Tauber, Annika Volke, Stephan Weidinger, Sally R. Wilkes, Andreas Wollenberg, Kim S. Thomas

Dermatology

Research output: Contribution to journal › Review article › peer-review

39 Citations (Scopus)

Abstract

Background

Atopic dermatitis (AD) is a chronic inflammatory skin disease. There are no standardized methods for capturing long-term control of AD.
Objective

We sought to identify how long-term control has been captured in published randomized controlled trials (RCTs). Results will initiate consensus discussions on how best to measure long-term control in the core outcome set for AD.
Methods

We conducted a systematic review of RCTs of AD treatments published between 2000 and 2013, with a follow-up period of 3 months or longer, at least 1 outcome measure recorded at 3 or more time points, full article available, and published in English.
Results

In all, 101 of 353 RCTs were eligible. Methods to capture long-term control included: repeated measurement of AD outcomes (92 RCTs; 91%), use of AD medication (29 RCTs; 28.7%), and AD flares/remissions (26 RCTs; 25.7%). Repeated measurements of AD outcomes were typically collected 3 to 5 times during a trial, but analysis methods often failed to make best use of the data. Time to first flare was most commonly used for trials including flare data (21/52). Medication use was recorded based on quantity, potency, and frequency of application.
Limitations

We included RCT data only.
Conclusion

This review illustrates the difficulties in measuring long-term control, and points to the need for improved harmonization of outcomes.

Original language	English
Pages (from-to)	1038-1044
Journal	Journal of the American Academy of Dermatology
Volume	75
Issue number	5
Early online date	10 Aug 2016
DOIs	https://doi.org/10.1016/j.jaad.2016.05.043
Publication status	Published - Nov 2016

Keywords

atopic dermatitis
atopic eczema
flares
long-term control
outcome measures
randomized controlled trials
systematic review

Access to Document

10.1016/j.jaad.2016.05.043

Cite this

Barbarot, S., Rogers, N. K., Abuabara, K., Aubert, H., Chalmers, J., Flohr, C., Hanifin, J., Naldi, L., Margolis, D. J., Paul, C., Ridd, M. J., Anna Schuttelaar, M.-L., Simpson, E., Tauber, M., Volke, A., Weidinger, S., Wilkes, S. R., Wollenberg, A., & Thomas, K. S. (2016). Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. Journal of the American Academy of Dermatology, 75(5), 1038-1044. https://doi.org/10.1016/j.jaad.2016.05.043

@article{db13967571714b1fbde5f14e6b4e58b4,

title = "Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review",

abstract = "BackgroundAtopic dermatitis (AD) is a chronic inflammatory skin disease. There are no standardized methods for capturing long-term control of AD.ObjectiveWe sought to identify how long-term control has been captured in published randomized controlled trials (RCTs). Results will initiate consensus discussions on how best to measure long-term control in the core outcome set for AD.MethodsWe conducted a systematic review of RCTs of AD treatments published between 2000 and 2013, with a follow-up period of 3 months or longer, at least 1 outcome measure recorded at 3 or more time points, full article available, and published in English.ResultsIn all, 101 of 353 RCTs were eligible. Methods to capture long-term control included: repeated measurement of AD outcomes (92 RCTs; 91%), use of AD medication (29 RCTs; 28.7%), and AD flares/remissions (26 RCTs; 25.7%). Repeated measurements of AD outcomes were typically collected 3 to 5 times during a trial, but analysis methods often failed to make best use of the data. Time to first flare was most commonly used for trials including flare data (21/52). Medication use was recorded based on quantity, potency, and frequency of application.LimitationsWe included RCT data only.ConclusionThis review illustrates the difficulties in measuring long-term control, and points to the need for improved harmonization of outcomes.",

keywords = "atopic dermatitis, atopic eczema, flares, long-term control, outcome measures, randomized controlled trials, systematic review",

author = "Sebastien Barbarot and Rogers, {Natasha K.} and Katrina Abuabara and Helene Aubert and Joanne Chalmers and Carsten Flohr and Jon Hanifin and Luigi Naldi and Margolis, {David J.} and Carle Paul and Ridd, {Matthew J.} and {Anna Schuttelaar}, Marie-Louise and Eric Simpson and Marie Tauber and Annika Volke and Stephan Weidinger and Wilkes, {Sally R.} and Andreas Wollenberg and Thomas, {Kim S.}",

year = "2016",

month = nov,

doi = "10.1016/j.jaad.2016.05.043",

language = "English",

volume = "75",

pages = "1038--1044",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier",

number = "5",

}

Barbarot, S, Rogers, NK, Abuabara, K, Aubert, H, Chalmers, J, Flohr, C, Hanifin, J, Naldi, L, Margolis, DJ, Paul, C, Ridd, MJ, Anna Schuttelaar, M-L, Simpson, E, Tauber, M, Volke, A, Weidinger, S, Wilkes, SR, Wollenberg, A & Thomas, KS 2016, 'Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review', Journal of the American Academy of Dermatology, vol. 75, no. 5, pp. 1038-1044. https://doi.org/10.1016/j.jaad.2016.05.043

TY - JOUR

T1 - Strategies used for measuring long-term control in atopic dermatitis trials

T2 - A systematic review

AU - Barbarot, Sebastien

AU - Rogers, Natasha K.

AU - Abuabara, Katrina

AU - Aubert, Helene

AU - Chalmers, Joanne

AU - Flohr, Carsten

AU - Hanifin, Jon

AU - Naldi, Luigi

AU - Margolis, David J.

AU - Paul, Carle

AU - Ridd, Matthew J.

AU - Anna Schuttelaar, Marie-Louise

AU - Simpson, Eric

AU - Tauber, Marie

AU - Volke, Annika

AU - Weidinger, Stephan

AU - Wilkes, Sally R.

AU - Wollenberg, Andreas

AU - Thomas, Kim S.

PY - 2016/11

Y1 - 2016/11

N2 - BackgroundAtopic dermatitis (AD) is a chronic inflammatory skin disease. There are no standardized methods for capturing long-term control of AD.ObjectiveWe sought to identify how long-term control has been captured in published randomized controlled trials (RCTs). Results will initiate consensus discussions on how best to measure long-term control in the core outcome set for AD.MethodsWe conducted a systematic review of RCTs of AD treatments published between 2000 and 2013, with a follow-up period of 3 months or longer, at least 1 outcome measure recorded at 3 or more time points, full article available, and published in English.ResultsIn all, 101 of 353 RCTs were eligible. Methods to capture long-term control included: repeated measurement of AD outcomes (92 RCTs; 91%), use of AD medication (29 RCTs; 28.7%), and AD flares/remissions (26 RCTs; 25.7%). Repeated measurements of AD outcomes were typically collected 3 to 5 times during a trial, but analysis methods often failed to make best use of the data. Time to first flare was most commonly used for trials including flare data (21/52). Medication use was recorded based on quantity, potency, and frequency of application.LimitationsWe included RCT data only.ConclusionThis review illustrates the difficulties in measuring long-term control, and points to the need for improved harmonization of outcomes.

AB - BackgroundAtopic dermatitis (AD) is a chronic inflammatory skin disease. There are no standardized methods for capturing long-term control of AD.ObjectiveWe sought to identify how long-term control has been captured in published randomized controlled trials (RCTs). Results will initiate consensus discussions on how best to measure long-term control in the core outcome set for AD.MethodsWe conducted a systematic review of RCTs of AD treatments published between 2000 and 2013, with a follow-up period of 3 months or longer, at least 1 outcome measure recorded at 3 or more time points, full article available, and published in English.ResultsIn all, 101 of 353 RCTs were eligible. Methods to capture long-term control included: repeated measurement of AD outcomes (92 RCTs; 91%), use of AD medication (29 RCTs; 28.7%), and AD flares/remissions (26 RCTs; 25.7%). Repeated measurements of AD outcomes were typically collected 3 to 5 times during a trial, but analysis methods often failed to make best use of the data. Time to first flare was most commonly used for trials including flare data (21/52). Medication use was recorded based on quantity, potency, and frequency of application.LimitationsWe included RCT data only.ConclusionThis review illustrates the difficulties in measuring long-term control, and points to the need for improved harmonization of outcomes.

KW - atopic dermatitis

KW - atopic eczema

KW - flares

KW - long-term control

KW - outcome measures

KW - randomized controlled trials

KW - systematic review

U2 - 10.1016/j.jaad.2016.05.043

DO - 10.1016/j.jaad.2016.05.043

M3 - Review article

SN - 0190-9622

VL - 75

SP - 1038

EP - 1044

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 5

ER -

Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review

Abstract

Keywords

Access to Document

Fingerprint

Cite this